In fiscal 2026, Walmart U.S. represented 68.4% of sales, Walmart International 18.5%, and Sam’s Club 13.2%, showing strong domestic reliance.

Walmart trades at fair value and fundamentals have consistently improved in the past.

Walmart is still getting stronger but becoming capital hungry.

Looking at the table above we see great progress over the past 7 years:

• Revenue grew from $524bn to $713bn between FY2020 and FY2026, up 36% which is in line with a non-cyclical market

• EBITDA margin remained remarkably stable at around 6%, while net margin improved slightly to 3.1%.

• Yet free cash flow went from $15.3bn to $14.9bn.

The reason is reinvestment.

• Capex rose from approximately $10bn to $26bn, absorbing much of the additional operating cash flow. Capex as % of revenue may appear minor at 1.0% to 3.7% but given the enormous revenue, that tiny change makes a big difference.

For every $100 of revenue, Walmart now spends $3.70 on capital investments and retains only $2.10 in free cash flow. Consequently, capital efficiency is low at 4.8% ROIC - measuring the return on each dollar invested. A value above 8% would be desirable for Walmart to create value.

The latest quarter is not changing the picture.

There are encouraging signs.

Q2 operating margin rose from 4.1% to 5.0%, lifting operating profit 29% on just 6% revenue growth.

But much of the improvement came from $2.9bn in tariff refunds. Higher-margin advertising and membership income also helped, while insurance, healthcare and depreciation costs pushed expenses higher.

The underlying business is improving, but the margin gain is not a reliable measure of recurring profitability.

And despite stronger profits, first-half free cash flow fell 20% as capital spending continued to accelerate.

A form of margin expansion illusion

We see revenue rising, operating margin expanding significantly but capital investments rising by an even higher rate resulting in no free cash flow (FCF) growth and a weak return on capital.

Recall that FCF is calculated as the operating cash flow minus capital investments. It is the money freely available to shareholders after making all payments necessary to keep operations running.

A margin expansion illusion is a recurring financial pattern commonly observed across businesses. See more patterns here.

What return can we expect on an investment in the stock in 5 years?

Today, Walmart trades around 38x trailing earnings, with a free cash flow yield of just 1.8%.

That is a demanding valuation for a company growing revenue around 5% annually.

A 1.8% FCF yield means investors pay roughly $56 for every $1 of annual free cash flow.

Walmart also raised full-year capex guidance from 3.5% to approximately 4% of sales resulting in a FCF for year end of just $ 11bn.

Scenario 1 = earnings growth continues

• Over the past 3 years Walmart grew earnings at 12%. We assume growth to continue and FCF to grow at a similar rate as investments start to materialise. Trading multiples are left unchanged.

• Investors would face a 3-5% annual return on their investment.

Scenario 2 = a 10% increase in stock price

• Such a business must deliver reliably on earnings and FCF and would not be expected to trade at higher multiples than today.

• Investors would have to expect a 20-25% growth on earnings and free cash flow per year to achieve that goal. If multiples expand further, to 1.5% FCF yield and 45x earnings, the growth would be closer to 15-20% on both metrics.

Scenario 3 = multiples normalise as growth fades

• Fading growth or delayed returns on capital spending can cause multiples to compress. I assume a business with Walmarts economics to trade closer to a 3% FCF yield and 30x earnings while growth remains close to 10%.

• Investors would face an annual loss of 5-7% for the next 5 years.

To justify the current price, Walmart must eventually convert its digital expansion and infrastructure investments into growth and substantially higher cash generation. Much of which is already reflected in the share price.

The stock trades around the upper end of the X-Ray fair-value band, leaving limited room for disappointing returns on investment.

That doesn’t mean its investments are failing. Automation, fulfilment infrastructure and technology can take years to pay off.

But until those investments produce higher cash flow, improving accounting profits alone are not enough to justify a higher share price. Currently a HOLD.

The insight

Walmart is becoming a better business.

Its digital platform is growing, advertising is expanding and operating profitability is improving.

But free cash flow remains close to where it stood six years ago, while capital requirements have increased substantially.

The investment case depends on whether today’s spending delivers tomorrow’s cash flow.

At the current valuation, much of that improvement already appears anticipated.

Financial X-Ray verdict: Hold.

The business is performing well. The cash returns have more to prove.

The Financial X-Ray is a digital analyst screening the investment universe for quality, helping you find investment opportunities.

As a free subscriber you have access to over 100 stocks. The X-Ray tells you exactly where strengths and pain points sit.

Financial X-Ray

Thanks for reading and supporting my work!

Most revenue comes from recurring software subscriptions, supplemented by implementation and consulting services.

The Financial X-Ray reveals something unusual: while Veeva’s share price repeatedly surged and collapsed, revenue, profits and cash flow kept moving almost uninterrupted in one direction.

This consistency is visualised by the straight, upward sloping fair value band.

The stock is volatile, the financials are not

Veeva’s economics have been unusually consistent.

• Revenue increased from $1.1bn in FY2020 to $3.2bn in FY2026, without a single down year.

• Since FY2021, FCF increased from $543m to $1.39bn.

More recently, profitability accelerated and moved beyond sector norms. In the last 3 years:

• EBITDA margin improved 26.3% 39.0% since FY2024

• Net margin rose from 22.2% to 28.4%

• ROIC that measures the return on each dollar invested climbed from 9.0% to 12.8%

Meanwhile, Veeva accumulated $1.3bn of net cash having paid down all of its debt.

The business became larger, more profitable and financially stronger simultaneously, without adding debt. That is rare!

And growth is accelerating again

The first half of 2026 strengthened the case.

• Revenue increased 17%, and EBITDA grew 26%. Over the past 4 years revenue grew closer to 14% while EBITDA increased 23% year-over-year.

I’d like to state here that one exceptional quarter should not change a valuation thesis. Instead, it should add confidence to the existing one.

Management subsequently raised full year guidance to approximately $3.68bn revenue (growth of 15%) and net income of $1,538 (an increase of 69%)

So the current trajectory is more than just consistent. Growth is running above its recent historical rate while profitability improves.

The valuation changes far more dramatically than the economics underneath it.

There is no obvious negative Financial X-Ray patterns here. The most expensive investment mistakes are summarized on my website.

Expensive investment mistakes

Instead, I want to highlight the disconnect between business volatility and stock volatility.

Veeva’s share price has repeatedly moved 30–50% while its revenue trajectory barely changed.

Investors frequently treat price volatility as evidence of business uncertainty. With Veeva, the historical financials suggest the opposite.

50x earnings isn’t the whole valuation story!

Veeva trades at approximately 49x trailing earnings. Expensive.

But management’s 2026 guidance of 1,538$ non-GAAP earnings puts the same $44bn market capitalisation at roughly 30x forward non-GAAP earnings.

As a side note: results have consistently exceeded expectations over recent years, supporting confidence in management guidance and outlook reliability.

So 30x is still a premium valuation, but it is very different from 50x.

Let’s look at the following investment scenarios for the next 5 years:

Scenario 1: conservative

• growth continues at ~15% p.a. in line with history, margins remain at current levels, no further improvements assumed. Such a business would trade realistically at 35x earnings and 3% FCF yield.

• Given Management’s estimates for 2026, investors would yield a 16-19% annual stock return, a decent resutl,

Scenario 2: let’s only expect a 10% annual return on the stock

• I start from the lower range of 2026 estimates and assume a slight contraction of valuation multiples (30x earnings, 3.5% FCF yield) which is realistic for such a business.

• Implied annual growth: 9-12% on both, earnings and free cash flow, very achievable.

Verdict: Veeva’s continuous fundamental improvements and light asset structure make an implied growth rate of 15% p.a. very likely. While valuation multiples can always swing, scenario 1 offers a realistic trading range for this stock making it a clear BUY.

The Financial X-Ray evaluates the stock correctly and visualised the fair value for you. (see chart above) You can do the same for 800+ stocks in a few clicks using the Financial X-Ray

Access the Financial X-Ray

What could make the thesis even better?

AI provides optionality on top of Veeva’s business.

Vault CRM is Veeva’s software for managing how pharmaceutical companies interact with doctors and other healthcare professionals. More than 180 customers are now live, and 12 of the world’s top 20 biopharma companies have committed to the platform.

Veeva Falcon is designed to automate work across clinical, regulatory and safety processes, with five early adopters already testing the platform.

Veeva hasn’t disclosed enough to quantify the revenue opportunity yet.

But that’s the attraction: the core business is already growing 15%. These new products provide upside and are not required to rescue growth. Looking at the current and planned capital expenditure, which is very low, I see little downside risk in AI.

The insight

Veeva demonstrates why a high P/E alone tells investors very little.

The stock is volatile. The business isn’t.

Revenue has nearly tripled since FY2020. FCF has more than doubled since FY2021. Margins are expanding. Growth is in the high teens. The balance sheet carries billions in excess liquidity.

And forward earnings are already reducing the apparent valuation significantly.

Veeva isn’t a bargain.

But consistency at a high level deserves a premium and the current numbers suggest the current price remains attractive.

Financial X-Ray verdict: Buy.

Veeva is also part of the Financial X-Ray Selection, where we track companies whose combination of quality, growth and valuation remains attractive enough to own.

Thanks for reading,

Nick

Falling margins and returns are concerning, strong cash flow is misleading

Danaher’s problem is direction.

• Revenue peaked at $29.5bn in 2021, before falling to $24.6bn in 2025.

• EBITDA margin fell from 35.6% to 28.3%

• Net margin decreased 27.1% to 14.7%

• Return on each dollar invested fell below the cost of capital threshold which is value destructive: ROIC decreased 8.7% to 6.1%

All four moved in the wrong direction.

FCF, however, remained strong at $5.3bn in 2025. That’s dangerous because it makes Danaher look healthier than the deterioration underneath it. FCF is also determined by acquisitions that took place in the past. Look at the swings as shown by capex as % of revenue in the table above. What an analyst concludes here is simple: a lack of predictability.

2026 still doesn’t look like a breakthrough

Management currently expects only 3–4% core revenue growth for 2026.

That’s all right and it is evidence of a recovery, but not yet a return to the economics Danaher produced earlier in the decade. The distinction becomes important when we look at valuation later.

The pattern you should look out for: Balance sheet mirage

This resembles a softer version of the Balance Sheet Mirage where operating metrics decline and the balance sheet remains robust.

Danaher isn’t financially distressed as shown by 2x Net debt/EBITDA. Banks start to worry if this ratio increases which it doesn’t. In addition, cash generation remains excellent.

But financial resilience shouldn’t be confused with improving economics.

Why Wall Street may be ahead of the financials

Danaher currently trades at 42x TTM earnings, 24x EV/EBITDA, 3.5% FCF yield. These are elevated metrics above usual sector levels.

Management expects a 3-4% growth for 2026 and mid single digit growth for the mid term.

Consider the following scenarios to see what investors can expect over the next 5 years:

Scenario 1:

• A business growing at 4% annually for the next 5 years will trade at a more mature PE of ~30x and a FCF yield of ~4%. The premium valuation we currently see will fade.

• In that case, Investors will absorb a loss of 2-5% annually.

Scenario 2:

• We aim for a return of 10% p.a for the next 5 years in line with the S&P 500. A stock growing at that rate could realistically trade at 45x earnings and a generous 3% FCF yield.

• This requires an annual growth of 9-11% on free cash flow and net income. Now look at the table above. This is highly unlikely given the swings we saw in the past and given that 2026 is not changing the picture.

What is realistic?

Since 2022 Danaher has not grown sales at all and acquisitions made free cash flow volatile. But on the other hand, Danaher’s revenue base is unusually defensive: roughly 83% of Q2 2026 revenue was recurring and it is very predictable.

Valuation appears defensible given the revenue stability but I am worried about deteriorating operating metrics and a lack of growth drivers.

The stock is fairly valued but the operating weakness make it a SELL. The Financial X-Ray evaluates financial health and growth and derives a fair value as shown below.

Wall Street is optimistic and may ultimately be right but investors are being asked to pay for part of the recovery before it appears fully in the financial statements.

What could change the picture?

A breakthrough patent probably isn’t it.

Danaher’s moat comes more from its installed equipment, consumables, workflows and recurring customer relationships than from one blockbuster product.

The more important catalyst is bioprocessing.

Q2 2026 bioprocessing orders grew mid-teens despite revenue being affected by project timing. Management also expects Biotechnology to grow mid-single digits for the full year.

If those orders convert into sustained revenue growth while margins recover, Danaher’s financial trajectory could finally turn.

That’s what I would watch, not the next product announcement.

The insight

Danaher is financially strong enough to hide an uncomfortable trend.

Revenue: down from its peak.
Margins: down.
ROIC: down.
ROE: down.
FCF: still strong.

That last number makes the company easy to like.

But strong cash generation doesn’t automatically mean improving business economics. Wall Street is effectively betting that Danaher’s bioprocessing recovery will reverse several years of deterioration.

It might. The Financial X-Ray simply isn’t seeing enough evidence yet to pay a premium for it.

Verdict: SELL.

These insights were produced by the Financial X-Ray, a tool that helps you see strength, weakness and fair value in seconds. This is not where research should end. This is where it begins.

Financial X-Ray

3 years ago the Financial X-Ray was built - a digital financial analyst that evaluates 800+ stocks based on the following criteria:

• Financial health (profitability, cash generation, capital efficiency, debt etc.)

• Growth (trend and stability of these metrics over time)

• Management quality (ownership dilution, M&A, forecast accuracy, buybacks)

• Valuation (compared to peers and adjusted for growth and financial health)

Stocks that score well across all 4 categories receive an X-Ray score of STRONG and are selected for the portfolio.

The X-Ray identifies strong businesses at fair prices.

A 10% margin can be excellent or poor depending on the sector and depending on the stability of this isolated number.

The X-Ray knows sector specific thresholds, and adjusts the valuation multiples accordingly.

These 5 stocks show the strongest score among S&P 100 comps and are included in the selection

Alphabet, Mastercard, Meta, Procter & Gamble, Visa are all economic powerhouses but the more interesting part is why these stocks were selected.

They combine above sector profitability, cash generation, stability and growth with a decent valuation.

The full reports are available through the X-Ray platform. As a free subscriber you have full access to the S&P 100 universe.

Subscribe now

Behind the paywall I reveal all 40 portfolio holdings and another 16 companies that are currently rated as BUY.

Read more

The difference between a bargain and a value trap may depend less on today’s earnings than on where fertilizer prices go next.

What changed beneath the surface

Revenue: The commodity cycle dominates

CF’s revenue increased from $4.1 billion in 2020 to $11.2 billion in 2022, before collapsing to $6.6 billion in 2023 and $5.9 billion in 2024. The 2022 surge reflected extraordinary fertilizer market conditions, including disruptions to global energy and fertilizer supplies. When those conditions normalized, revenue fell 41% in a single year. Even after recovering 19% in 2025, sales remained 37% below their 2022 peak.

The problem is that commodity pricing can overwhelm the underlying business trajectory.

Margins: Exceptional, but difficult to normalize

CF’s EBITDA margin reached an extraordinary 56.1% in 2022, before declining to 46.5% in 2025. Those margins remain impressive for a capital-intensive commodity producer. They reflect CF’s competitive production costs (access to cheap North American natural gas) and efficient facilities.

But look closer: EBITDA fell from $6.3 billion in 2022 to $2.8 billion in 2024, a decline of 55%. So the profitability generated by the cost advantage is not durable.

Cash flow: Strong, but not predictable

Free cash flow followed the same pattern: $924 million in 2020, $3.4 billion in 2022, $1.0 billion in 2023 and $1.8 billion in 2025.

The 2023 collapse was particularly revealing. Capex jumped to 26% of revenue, while earnings normalized from their exceptional peak. That combination reduced FCF by almost 70% in one year.

Cyclical capital efficiency and the balance sheet

The commodity cycle also appears in capital returns. ROIC surged to 42.5% in 2022, then declined to 15.2% in 2025. That is still respectable, but it shows how strongly profitability affects the return generated by CF’s asset base.

The balance sheet is considerably more reassuring. Net debt/EBITDA declined from 2.3x in 2020 to 0.6x in 2025, giving CF substantial financial flexibility.

Management has also aggressively repurchased shares. CF’s financial strength reduces the risk of surviving a downturn. It does not eliminate the earnings downturn itself.

And what about H1 2026?

The latest results look impressive. Revenue increased 18% to $4.2 billion, while net income nearly doubled to $1.34 billion. But the source of that growth matters: fertilizer sales volumes actually fell 11%, while average selling prices increased 33%. In other words, the earnings surge came primarily from stronger nitrogen prices, not higher underlying volumes. FCF grew roughly 14% higher.

The pattern at work: The Peak Earnings Trap

The financial pattern is straightforward:

• Commodity prices rise, lifting revenue and margins.

• Earnings and FCF accelerate, making valuation multiples appear unusually low.

• Investors extrapolate favorable market conditions.

• Commodity prices normalize, reducing profits and raising the effective valuation.

Management is running an efficient business. But operational excellence cannot make global fertilizer prices predictable.

What does this mean for valuation?

As of October 2026, the stock trades at approximately 12.2x TTM earnings, 4.8x EV/EBITDA and a 10.2% FCF yield.

Those numbers look inexpensive but looking at the table above, we see that this cheap valuation is the result of a lack of predictability and volatile financials.

A high FCF yield is attractive only if the underlying cash flow is sustainable.

Management expects mid-cycle 2030 EBITDA to come it at $3.3 billion and FCF at $1.7 billion which is essentially no growth.

Scenario 1:

• Assuming a FCF yield of 8% and a PE of 15x in 5 years and taking into account Management guidance, we arrive at 4-5% annual return on our investment. This is not a satisfactory performance.

Scenario 2:

• A 10% p.a stock increase requires an annual growth of 5% across key financial metrics. This is a challenging assumption from current levels.

If fertilizer prices normalize and earnings fall toward weaker-cycle levels, much of the appearant discount disappears. The valuation depends more on future nitrogen prices than the headline multiple suggests.

This leaves us with a final HOLD rating as indicated by the fair value band below.

Everything you’ve read so far has been detected by the Financial X-Ray - an automated platform that evaluates companies through growth, profitability, cash generation, capital efficiency, balance-sheet strength, management quality and valuation. Here is an example of the screener output.

Access the X-Ray

The insight & verdict

CF Industries is not a weak company hiding behind a low valuation.

It has an efficient production network, exceptionally strong margins, manageable debt and substantial cash generation.

The weakness is earnings visibility.

H1 2026 demonstrates how much CF can earn when nitrogen prices are favorable. Its history demonstrates how quickly those earnings can disappear when conditions change.

Before calling CF a Buy, I would want a clearer margin of safety against normalized earnings, not simply another strong quarter.

Financial X-Ray verdict: HOLD.

Forecasting LVMH is particularly interesting as stock price and underlying quality are not pointing in the same direction.

LVMH sells luxury goods in the following segments: Fashion & Leather Goods (47% of sales), Selective Retailing (23%) , Watches & Jewelry ( 13%) and the remainder coming from Perfumes & Cosmetics, and from Wines & Spirits.

What changed beneath the surface

Financial metrics never move in isolation. When read together, they often reveal structural dynamics beneath the surface of a business. (Full framework)

Let’s look at LVMHs most relevant Financial metrics summarized by the Financial X-Ray, a digital analyst that tells you where pain points and strengths sit.

• Revenue surged from $60.2bn in 2019 to $95.1bn in 2023, an annual growth rate of 12% supported by the reopening of luxury spending, pricing and exceptionally strong demand after the pandemic despite inflation. But that momentum broke: revenue fell 7.8% in 2024 before recovering 8.2% to $94.9bn in 2025. The reasons: normalization after Covid, weak China demand and currencies that moved against LVMH.

• Profitability tells the same story. EBITDA margin jumped from 29.7% in 2019 to 35.0% in 2021, then steadily declined to 31.6% in 2025. Net margin fell even more, from 18.7% to 13.5%. That is still decent profitability, but it shows that the extraordinary post-Covid economics have faded with weakness concentrated particularly in Fashion & Leather Goods and Wines & Spirits.

• Free cash flow (Operating cash flow - investments (Capex)) however increased from $6.5bn in 2019 to $15.7bn in 2025, even as earnings and margins weakened.

  Capex also fell to 6.8% of revenue, versus roughly 10% before the pandemic. That makes the deterioration less worrying: LVMH is not consuming more capital simply to defend slowing growth. It is converting a mature revenue base into substantial cash.

• Capital efficiency, however, has not returned to peak levels. ROIC which measures the return on each dollar invested, improved from 8.3% in 2020 to 13.3% in 2021, but was only 13.0% in 2025, ROE has fallen much more dramatically, from 27.6% in 2021 to 17.1%.

• Debt levels are not the problem. Net debt was $32.8bn in 2025, and leverage (Net debt divided by EBITDA remained only 1.1x, almost unchanged from 2019. A level below 2x is nothing to worry about in this industry.

If you are new to these metrics consider reading one of the methodology artilces that explain what metrics matter and why:

Methodology

Together LVMH used to combine strong margins with strong growth and returns on capital. Such a situation demands premium valuation. Today the margins remain good, but the growth and return profile is less exceptional.

And what about H1 2026?

H1 suggests stabilization. Revenue fell 3% reported, yet grew 2% organically as currencies reduced reported growth by five percentage points. That is an increase by 3 percentage points more than in the first half 2025.

Free cash flow and EBITDA margins also stabilized at $6.5bn and 26% respectively, the same result as in H1 2025.

The pattern investors face

So as investors don’t face further deterioration from here, we do not look at a traditional Valuation Comfort Trap.

Instead:

• Revenue: stabilizing

• Margins: stable

• Free cash flow: expanding

• Capital efficiency: stagnating

• Capital spending & debt: disciplined

And how does this translate into a fair value?

A stock falling more than 30% can feel cheap. But price decline and undervaluation are not the same thing.

Today, LVMH trades around 19x TTM earnings and 6.4% FCF yield compared with with roughly 24–30x earnings and 3-4.5% FCF through much of 2021–2025.

The multiple has normalized because growth, margins and returns on capital have normalized. LVMH is no longer the growth machine with exceptional financials.

Let’s look at possible 5-year investment scenarios

Scenario 1 (conservative):

• Slow recovery continues, but China keeps stagnating and financials remain stable, growing at 5% p.a

• Multiples 2031 at normal sector levels of 25x earnings and 4.5% FCF yield

• Expected annual return on investment: 8-11%

Scenario 2 (optimistic):

• Luxury demand increases to 10% p.a causing a shift back to LVMHs older, higher profitability.

• Multiples 2031 would reflect that strength at a premium, 30x earnings and 3.5% FCF yield is assumed

• Annual return on investment: 18-20%

Now, what is realistic? The truth is certainly somewhere between both scenarios, so we look at a slightly undervalued company with decent return potential but not yet back at previous strength.

That’s exactly where the Financial X-Ray places the stock. The new reality of considerably lower growth and capital efficiency causes the fair value band to decline.

That assessment supports a Hold rather than a Buy until we have a better visibility on future demand.

The insight

LVMH’s problems increasingly look cyclical rather than evidence that its luxury economics have broken.

Margins remain exceptional, cash generation is resilient and organic growth is returning.

But that is only half the investment case.

The stock’s decline has already removed much of its former premium, while the business has moved from exceptional growth toward normalization.

For LVMH to become more compelling, growth would need to accelerate further or the valuation would need to offer a larger margin of safety.

Verdict: Hold.

How to spot a strong stock in seconds?

The Financial X-Ray is my digital financial analyst, readily accessible for you on my website. It helps you spot strengths and weaknesses of more than 800 stocks in seconds by analysing dozens of metics compared to industry, adjusted for growth and financial strength. It serves as a starting point or sanity check for your investment.

To the Financial X-Ray

The company operates in cyclical end markets and faces demand fluctuations based on construction, mining, and energy trends in multiple regions. Its largest segments demonstrate significant exposure to North America and split as follows:

• Construction Industries: ~39%

• Power & Energy: ~39%

• Resource Industries: ~22%

In order to understand if we should commit capital, we must look at the financials.

What changed beneath the surface

These signals rarely move in isolation. When read together, they often reveal structural dynamics beneath the surface of a business. (Full framework)

Caterpillar’s historical numbers hardly resemble a growth company.

• Revenue is cyclical. It rose sharply after the pandemic (22%) and the years after but has turned negative in 2024 ( -3.4%) before recovering slightly to 4.3% in 2025.

• Margins fluctuated with the cycle, are in line with the sector and have followed a stable sideways trend.

• ROIC declined from 12.2% to 8.9% indicating a severe decline in capital efficiency. Recall that ROIC must exceed the company’s cost of capital (8-10%) in order to create value for shareholders.

• FCF fell from $9.8bn in 2023 to $7.5bn in 2025 partly driven by capital spending and by demand shifts.

• Debt has remained stable at an elevated but acceptable level for the sector.

Then 2026 changed the trajectory.

• Q2 sales increased 24% to $20.5bn. AI infrastructure adds a new dimension: Q2 Power Generation sales increased 29%, driven partly by large engines and turbines for data centers.

• net profit rose 60% to $3.6bn, and net margin expanded from 13.3% to 17.6% . Importantly, $3.1bn of the $4.0bn sales increase of Q2 came from higher volume rather than price.

• The order backlog (secured contracts likely to translate into revenue) more than doubled in the first half of 2026 and stands at $72bn. That is more than the entire 2025 revenue.

In short: we see an improvement across the entire income statement and and increase in valuation multiples.

The pattern at work

Everything points to another form of durability overpricing here. Recall that this recurring pattern is characterized as follows.

And that’s exactly what we observe when we look at Caterpillar. But we must clarify what that means for valuation and for the durability of earnings first before concluding our thoughts. (See details on the pattern here).

Why investors may misread this phase and what return we can expect.

The acceleration has substance. Managements states that 59% of the magnificent order backlog is expected to convert within 12 months. That alone provides unusually strong visibility for a cyclical industrial company. In addition, growth has reaccelerated, margins are expanding and capital spending remains disciplined.

So, Caterpillar deserves a higher valuation than its 2024–25 numbers alone suggest. But investors have already repriced that improvement.

Caterpillar trades at 42x PE and 2% FCF yield - levels associated with tech and growth companies. So let’s look at 3 Scenarios as reliable estimates for the following five years:

Scenario 1 - conservative

• Normalized valuation of 30x earnings, 3.5% FCF yield

• Growth of 10% and reliable cash conversion in line with Management target (historical growth 0-10%)

Expected annual return = 7-9%.

Scenario 2 - optimistic

• Valuation stays elevated as growth turns out to be resilient. 40x earnings, 2.5% FCF yield

• Growth of 15% and reliable cash conversion

Expected annual return = 14-16%.

Scenario 3 - Financial X-Ray

The X-Ray adjusts the current valuation multiples determined by the market for growth and financial resilience to derive a fair value band.

The fair-value band is therefore placed below the stocks current price and suggests further downside.

The risk is not that growth disappears. It is that growth normalizes while the valuation multiple does the same.

Caterpillar still depends heavily on construction, mining and energy cycles. A larger backlog improves visibility, it does not eliminate cyclicality.

The insight

Caterpillar is becoming a better business.

The $72bn backlog, accelerating volumes and growing exposure to data-center power generation provide more visibility than Caterpillar historically enjoyed. Management also appears to be investing into demonstrated demand rather than stretching the balance sheet to manufacture growth.

But the stock has changed even faster than the business.

Investors are no longer paying a cyclical-company valuation for Caterpillar. They are increasingly paying for structural growth.

That can work if today’s growth proves durable. But at the current valuation, simply remaining an excellent cyclical industrial company may no longer be enough.

If you’ve made it this far take a closer look at the Financial X-Ray

The tool helps you “X-Ray” more than 800 stocks in seconds so you know where strengths and weaknesses sit across financials, management, growth and valuation.

It’s a screener for analysed conclusions, not raw metrics.

Stocks that perform well on all categories have outperformed the S&P 500 by more than 50% over the past 3 years.

Leave me a comment or send a DM, I’m always here for questions and discussions. Here’s the way to the X-Ray: Thanks for reading.

Financial X-Ray

The company supplies the physical infrastructure data centers need to operate (power management, cooling systems and related services). More powerful AI chips require more electricity and generate more heat, making this infrastructure increasingly important.

And that opportunity is already visible in Vertiv’s numbers. The company getting stronger.

What changed beneath the surface

• Revenue increased from $4.4 billion in 2019 to $10.2 billion in 2025, that’s an annualised growth of 15% and accelerating as spending on data centers increases.

• EBITDA margin expanded from 9.2% to 20.9% which means that a much larger percentage of every revenue dollar now becomes operating profit. That’s a better improvement compared to peer companies.

• ROIC reached 14.6%. The company is generating increasingly attractive returns on the capital required to grow the business. This is a strong sign of efficiency.

• Net debt/EBITDA fell from 8.2x to 0.8x. Growth has therefore strengthened rather than stretched the balance sheet. A level below 2.0x is a solid basis for the sector.

• Free cash flow reached $709 million in 2025, but fell from $1.12 billion in 2024. This is the one metric that initially looks out of place. Vertiv is spending aggressively to increase capacity. Recall that FCF = Operating cash flow - capital spending which rose above 13% of sales in 2025. The good news: Management now expects capital spending to be $550–570 million for the full year 2026, roughly 4% of expected revenue. (so we’re back on track).

Q2 confirms the acceleration

Q2 revenue increased 24.1%, from $2.64bn to $3.27bn and profit grew even faster.

Gross profit increased 37.7%, operating profit 44.2% and net income 53.5%.

That’s considerably more important than the headline revenue growth. And management raised its expectations again.

Vertiv now expects roughly $14 billion of 2026 revenue, about 31% organic growth, adjusted operating margins of 23.3–24.3%, adjusted FCF of $2.4–2.6 billion and net income of $2.3bn ($1.3bn in 2025).

Now, compare that to the table above. That is highly attractive.

The devil is in the detail

Don’t extrapolate the current Q2 free cash flow. Why? Because during the first half, free cash flow is artificially increased by deferred revenue of $1.8bn (money the company collected but without having delivered the product). Over the next two years Vertiv only expects deferred revenue of $0.6bn. So there will be no further large inflows of that kind.

Consequently I’d conservatively forecast 2026 FCF as ~1.6bn (H1 FCF) x 2 - 1.8bn deferred revenue = ~1.4bn rather than 2.4-2.6bn adjusted management guidance.

Management states the following:

“This is a forward-looking non-GAAP financial measure that cannot be reconciled without unreasonable efforts for those reasons set forth under “NonGAAP Financial Measures” of this release.”

That basically means there are unpredictable swings in working capital. This is part of the reason why financials must be evaluated on an annual basis and over time instead of in isolation.

The pattern I see: Durability Overpricing?

Vertiv currently has almost everything investors want:

Revenue growth ↑
Margins ↑
Free cash flow ↑
ROIC ↑
Leverage ↓

That combination deserves a premium.

But what growth does the market currently expect given a market cap of $95bn? How do margins and cash flow have to develop to justify the price? Is Vertiv a clear BUY after the 35% drop?

That’s what I’ll reveal behind the paywall. The insights I am giving you in this article are detected by an automated digital analyst, the Financial X-Ray that recommended to BUY Vertiv in June 2023. It’s goal is to tell you in seconds where a company breaks. Check it out on my website, S&P 100 coverage is free.

Start the X-Ray

Read more

But what if I told you that anyone can actually do better than than. How? Simply by dropping the losers, the companies that trade at expensive multiples while displaying deteriorating financials and a weak outlook.

Let’s take a look at Americas largest companies in the S&P 100 and 7 stocks that are not worth owning at the moment and how to detect them in seconds.

What about the No-No-List?

Well, here we go.

But the more interesting question is: What do these companies have in common and why should we avoid them?

The problem is that today's valuation offers insufficient compensation for weak visibility into normalized margins, cash flow and returns on capital. Let’s examine these companies in detail over the past 5-7 years.

Boeing

• Financials: The recovery is visible, but not durable yet: FCF was still -$3.0bn in 2025, ROIC only 2.1%, and leverage remains heavy at 5.9x net debt/EBITDA.

• Valuation: Around 74x 2025 earnings and 21x EV/EBITDA is a demanding price for a company still rebuilding profitability and cash generation.

• Watch: Everything depends on execution, especially 737 MAX production rates, 737-7/10 certification and deliveries. Boeing recently acknowledged that 737 production has not stabilized at its targeted rate, which hit the stock. A better bet here is on Airbus.

Starbucks

• Financials: Growth stalled while EBITDA margin fell from 20.6% to 14.5% and ROIC from 14.7% to 8.0%. Debt rose while the economics weakened.

• Valuation: Roughly 51x 2025 earnings, 15.5x EV/EBITDA and just a 2.4% FCF yield leave little room for a disappointing turnaround.

• Watch: The Back to Starbucks turnaround is bringing customers back, but at considerable labor/reinvestment cost. The next question is whether traffic recovery actually converts into durable margin recovery, I don’t see it.

Intel

• Financials: Revenue fell from $79bn to $53bn, FCF remains negative and ROIC is around zero. Enormous capex has yet to produce attractive returns.

• Valuation: With negative earnings and FCF, investors are effectively paying today for future turnaround economics that haven’t arrived yet.

• Watch: Intel Foundry is the swing factor. It still lost $4.5bn in H1 2026, while Intel itself acknowledges the enormous investment and competitive challenge of taking on TSMC and other foundries. Technology is evolving quickly, trying to catch TSMC is huge hurdle.

General Motors

• Financials: EBITDA margin fell from 20.2% to 10.0%, ROIC is around 0.7%, and leverage remains high. Strong headline FCF hasn’t translated into consistently strong capital returns.

• Valuation: A 14% historical FCF yield looks cheap, but ~29x reported 2025 earnings tells a very different story. The problem is knowing what normalized earnings and FCF actually are.

• Watch: Tariffs and the EV reset. GM estimates 2026 tariff effects of $2.5–3.5bn (current EBITDA ~$20bn) and has already taken billions in EV-strategy charges. Q2 operations improved, but the range of outcomes remains unusually wide. GM must invest heavily while facing cost pressure everywhere, the result: unpredictable and negative free cash flows.

Ford

• Financials: Revenue barely moved while 2025 EBITDA and ROIC turned negative. FCF looks excellent, but the enormous swings between earnings, cash flow and returns make normalized profitability difficult to establish.

• Valuation: A 24.9% historical FCF yield screams cheap but only if that cash flow is repeatable. Negative earnings make conventional P/E essentially useless. BTW this is another example that shows why screening raw metrics is little helpful.

• Watch: Ford remains exposed to EV restructuring, tariffs, product mix and manufacturing execution. Q2 2026 improved materially, but it also contained $4.2bn of special charges (to compare: EBITDA = $10-15bn), largely related to BlueOval SK and EV cancellations. That’s exactly the visibility problem.

CVS Health

• Financials: Revenue climbed from $257bn to $402bn, yet EBITDA margin collapsed from 6.4% to 2.5%, ROIC fell to 2.3%, and leverage reached 8.6x net debt/EBITDA, that is an extreme value (> 3.0x times deserves attention).

• Valuation: The 7.3% FCF yield looks reasonable, but reported earnings imply a much richer valuation. Cheap cash flow alone doesn’t compensate for deteriorating returns and leverage.

• Watch: The big variable is Aetna’s medical-cost economics. Encouragingly, its medical benefit ratio improved to 87.4% from 89.9% in Q2 2026, but membership, Medicare Advantage economics and reimbursement remain crucial to whether that improvement proves durable.

AbbVie

• Financials: AbbVie generates substantial cash, but FCF, capex, margins and debt have been unusually lumpy. ROIC has fallen from 15.6% to 11.2%, while acquisitions make the underlying capital requirements harder to normalize.

• Valuation: A roughly 4.3% FCF yield offers limited compensation for that uncertainty. Reported P/E is distorted, so I would emphasize FCF yield and EV/EBITDA rather than the 96x headline P/E.

• Watch: The investment case increasingly rests on Skyrizi and Rinvoq replacing Humira and the pipeline / acquisition machine continuing to work. Those two drugs already represented about 42% of 2025 revenue, while AbbVie continues to use M&A including its proposed Apogee acquisition to replenish future growth.

And how do we detect these companies in seconds?

Before investing you should sanity check your stock pick for the exact same metrics discussed herein. Growth, margins, cash flow, capital spending, capital efficiency and debt often reveal a lot about the direction of the stock. If it company scores well on all of them it is not a guaranteed winner but the probability of a costly mistake is highly reduced.

The Financial X-Ray does the job for you in seconds, it tells you exactly what companies break and at what metric. It weighs the numbers for you.

A strong business follows a simple formula:

Quality = Strong financials + Strong Management + Decent outlook + reasonable price

Together that’s what gives a stock an X-Ray score of STRONG.

As a free subscriber you have access to all S&P 100 companies and their assessment including deep dive reports.

Paid subscribers have access to over 800 evaluated stocks and the X-Ray portfolio that invests in the best of them and has outpaced the S&P 500 significantly on a risk-adjusted basis and in absolute terms.

Access the X-Ray

In order to derive a fair value we must first look at the financials.

What changed beneath the surface

The strongest part of the FedEx story is cash generation. Free Cash Flow (FCF) surged 68% over the last year - a significant increase given the prior years range of $3-4bn.

FedEx did not become 68% more profitable. Free cash flow measures the money freely available to the business to pay shareholders. It is the amount generated by operating activities less investment spending (CAPEX).

A meaningful part of the cash-flow improvement came from spending less on the network. Capex fell to 4.0% of revenue, the lowest level in FedEx’s history. Investors should always favor a consistent evolution of this ratio (see metrics table).

FedEx has been simplifying its network, retiring aircraft and cutting structural costs. Management exceeded its $1bn transformation-related savings target in FY2026. Lower capital requirements could therefore represent a genuinely more efficient business.

But capex cannot keep falling indefinitely. Future FCF growth will increasingly need to come from higher operating profits.

And that is where the story becomes less convincing.

The latest Quarter shows the weakness

The latest quarter (fiscal year ended May 2026) showed how sensitive the business reacts to changes in the cost structure

FedEx generated $25bn of Q4 revenue, up 13%. Yet GAAP operating income fell from $1.8bn to $1.6bn, pushing operating margin down.

Demand wasn’t the problem. At Federal Express, package revenue increased 13%. U.S. domestic package yield increased 10%, while international priority yield increased 16%. FedEx was moving more packages and earning considerably more per package.

Costs simply moved faster.

Purchased transportation increased 15%, salaries and benefits 11%, and fuel expense jumped 66% from $864m to $1.4bn.

That is the weakness of a 10–12% EBITDA business. A relatively small change in costs can consume a large portion of operating profit.

FedEx’s returns on capital are moving in the right direction. ROIC has recovered from roughly 2% in 2022 to 6.9% in 2026, while ROE is around 15%. That matters because FedEx is generating better returns while reducing the capital required by the network.

There is genuine operational improvement underneath the numbers.

The pattern at FedEx

FedEx comes close to Cash Conversion Illusion or a valuation comfort trap, but it isn’t a textbook example.

• Revenue: rising but volatile

• Operating margins: flat but low

• FCF: Increasing (through lower CAPEX)

• Capex: Lowest % of revenue in company history

• ROIC: Improving

• Valuation attractive

Is FedEx cheap enough?

At roughly 17x earnings and a 6.8% FCF yield, FedEx doesn’t require extraordinary growth to justify its valuation.

That is attractive.

Management expects calendar 2026 revenue to grow approximately 11%, with adjusted EPS expected to decline by 5%.

But cheapness has to be considered alongside predictability.

FedEx operates an enormous physical network with aircraft, vehicles, facilities and hundreds of thousands of employees. Fuel prices, wages, transportation costs, trade policy and volumes can all move faster than the company can reprice its services.

Q4 demonstrated that risk in real numbers and the outlook shows that margin pressure is real.

13% revenue growth still produced lower operating profit. That makes a 6.8% FCF yield less compelling than the same yield from a business with 25% margins and low earnings volatility. Worth mentioning here is the elevated Net debt / EBITDA ratio near 3x - banks usually favour a value below 1.5x. The ratio is an indication for financial flexibility.

If you invested in FedEx stock today and expected a 10% return on your investment for 5 years, net income as well as free cash flow would have grow by ~7% per year in order for the stock to trade at slightly less depressed earnings multiple of 20x and a 6% FCF yield.

Now look at the history, we said margins are fairly stable (efficiencies offset cost explosion) but revenue fluctuates. Over the past 6 years revenue grew by an average of 2-3% or 4-5% including the pandemic year 2020.

If growth remains close to historical levels and margins remain resilient your expected annual return is roughly 7%.

Higher returns are only possible if growth picks up significantly and margins expand - but that is less likely to happen.

So where does it leave us?

Attractively valued yes, enough strength and resilience to outperform no. That’s exactly what the Financial X-Ray shows you by adjusting dozens of metrics and deriving a fair value band

The insight

FedEx is becoming a better business.

Costs have been removed, capital intensity has fallen, ROIC has improved and cash generation is stronger. The current valuation does not demand heroic growth.

But investors should be careful extrapolating the 68% increase in FCF.

Capex is already at a historical low. Margins remain thin. And Q4 showed that fuel and other operating costs can quickly overwhelm otherwise healthy revenue growth.

That leaves FedEx in an unusual position:

The valuation looks cheap and the improvement is real. The question is whether the improvement is resilient enough to deserve a higher valuation.

For now, I don’t think the evidence is strong enough.

Verdict: Hold and in line with the Financial X-Ray.

The X-Ray is the digital analyst I built, it helps me see strengths and weaknesses in relation to fair value in seconds. As a free subscriber you can use it as well. It is available though my website.

Financial X-Ray

Thanks for reading!

• It pulls financial and news data from 900+ stocks

• It analyses financials over time and benchmarks them against peers

• It weighs the metrics according to a defined scheme

The result is the Financial X-Ray portfolio that consists of 40 stocks and has performed well over the last 3 years. To track the performance I invested 100k to equal parts 3 years ago. If a new position is added or sold the portfolio is rebalanced proportionally.

3 years is not 20 years but it’s proof that the framework deserves attention.

Not many trades have been made. last month nothing was added or sold - it is a buy and hold portfolio aiming to avoid hype.

As a free subscriber you can use the tool freely on my website (S&P 100 coverage) https://www.theinsideanalyst.com/financial-x-ray

As a paid subscriber, you have access to over 900 stocks, the full X-Ray portfolio and the ability to build and roast your own portfolio by the X-Ray algorithm.

What’s inside the portfolio?

From the free S&P 100 universe the X-Ray portfolio holds and classifies these stocks as clean strong buys.

The common thread across these five companies is the ability to turn revenue into durable profits and cash, while maintaining financial flexibility. That is something equity analysts call resilience even in economic downturns. I focus on strong fundamentals over time, so one-off effects get eliminated. However, the most recent quarters support the historical trends in these cases.

1. Alphabet

• Growth and profitability: Revenue increased from $162bn in 2019 to $403bn in 2025, while EBITDA margin expanded from 31.8% to 44.9%. That combination points to substantial operating leverage and a business that has become more profitable as it scales.

• Financial resilience: Free cash flow reached $71.7bn, with net debt of just 0.2x EBITDA. The balance sheet provides flexibility to fund AI and Cloud investment without relying heavily on external financing.

• Quality of growth: Revenue quality is rated Strong, supported by stable growth across advertising and cloud. The main concern is capital intensity, with capex rising to 23.1% of revenue in 2025.

• Valuation: At 30.8x TTM earnings and a 1.8% FCF yield, Alphabet is not cheap on absolute multiples. The X-Ray nevertheless rates valuation Strong, reflecting its growth and financial quality. Future returns on elevated AI investment will be important to justify the premium.

2. Meta

• Growth and profitability: Revenue rose from $70.7bn in 2019 to $201bn in 2025, while EBITDA margin increased from 49.1% to 52.0%. The advertising platform continues to generate exceptional profitability at scale.

• Cash and balance sheet: Free cash flow reached $41.9bn and leverage remains low at 0.5× EBITDA. This gives Meta the capacity to fund large investments, although net debt has increased.

• The key trade-off: Capex rose to 36.8% of revenue and ROIC fell to 5.1% in 2025. The business remains strong, but the economics of the AI investment cycle are now central to the thesis.

• Valuation: At 26x TTM earnings and a 2.7% FCF yield, Meta trades at a lower earnings multiple than Alphabet despite similarly strong profitability. The X-Ray rates valuation Strong, but the discount must be weighed against heavier capital spending and execution risk.

3. Visa

• Durable profitability: Revenue grew from $23.0bn in 2019 to $40.0bn in 2025, while EBITDA margins remained between 65% and 72%. Even during 2020, revenue declined only 4.9%, demonstrating the resilience of the payment network.

• Exceptional capital efficiency: ROIC improved from 18.7% to 24.3%, and free cash flow reached $20.7bn. These figures support the X-Ray’s assessment of sector-leading margins and returns.

• Financial strength: Net debt is only 0.2x EBITDA, leaving substantial flexibility for buybacks, dividends and investment without stretching the balance sheet.

• Valuation: Visa trades at 34.9x TTM earnings and a 3.0% FCF yield. The premium is supported by unusually stable margins, strong returns and low leverage. The X-Ray rates valuation Strong, although the multiple leaves less room for disappointment.

4. Mastercard

• Consistent growth: Revenue nearly doubled from $16.9bn in 2019 to $32.8bn in 2025, with growth of 16.4% in the latest year. EBITDA margins remained around 60–62%, showing that expansion has not come at the expense of profitability.

• Outstanding returns: ROIC increased from 34.4% to 36.5%, while free cash flow reached $16.9bn. The X-Ray rates revenue and EBITDA quality Strong, reflecting growth and execution that compare favourably with sector norms.

• Balance sheet: Net debt stands at only 0.4x EBITDA, supporting continued investment and shareholder returns.

• Valuation: At 33.9x TTM earnings and a 3.3% FCF yield, Mastercard is priced for quality. The X-Ray rates valuation Strong, supported by its combination of double-digit growth and exceptional capital efficiency. The key question is whether those returns can remain durable as the business scales.

5. Procter & Gamble

• Defensive revenue: Sales increased from $71.0bn in 2020 to $87.0bn in 2026, without an annual decline. Growth is modest, but the consistency reflects recurring demand across essential consumer categories.

• Stable profitability and cash: Net margins stayed between 17.7% and 19.0%, while annual free cash flow remained above $12bn. This supports the X-Ray’s assessment of strong cash generation and resilience through changing economic conditions.

• Conservative leverage: Net debt is 1.2× EBITDA, while the dividend yield is 2.9%. For a business in the defensive sector these are very good levels.

• Valuation: At 21.7x TTM earnings and a 4.5% FCF yield, P&G offers a higher cash-flow yield than the other four companies. The X-Ray rates valuation Strong, but with revenue growth of only 3.3% and EBITDA margin falling to 24.4% in 2026, the investment case depends on stability and cash returns rather than accelerating growth.

These businesses can hardly be called speculative. They form part of the portfolio and remain attractively valued even today.

Behind the paywall I’ll reveal 5 more companies that are part of the X-Ray selection, still at attractive levels and with decent upside potential and I also reveal the entire 40 stock portfolio.

2 Companies in the financial sector, 1 Real estate player, 1 BioTech comp and 1 Software business (4 of which are US companies and 1 European stock).

Read more

It designs custom AI chips and networking equipment for hyperscalers, alongside an infrastructure software business.

In easy words, think of Broadcom like this: You can’t see what they make, but without them, the internet wouldn’t work!

• They design the specialized chips inside smartphones, Wi-Fi routers, and massive data centers that allow devices to communicate and stream data at high speeds.

• They provide heavy-duty software (primarily through their VMware division) that helps large corporations, banks, and governments manage their cloud networks.

The stock has stagnated so far this year (only up 3.3%) while sales are on track to grow 66% in 2026 alone while earnings could nearly double.

So the question is: Can the next five years deliver enough growth to justify the price of $1.7T? To understand it we must look at the numbers.

What changed beneath the surface

• Broadcom’s revenue increased from $22.6bn in 2019 to $63.9bn in 2025. The VMware acquisition contributed significantly to the step-change in 2024, so the historical growth rate is not purely organic.

• Operating margin (EBITDA) measuring the profitability of the core business has remained above 50%, an exceptionally high number.

• Free cash flow scaled as the business grew. 2024 marks an exception as the company spent ~60bn on the acquisition of VMware.

• ROIC and ROE measure the efficiency of each dollar spent. Values above 15-20% mark an outstanding business.

And what about 2026?

• Q3 revenue rose 86% to $29.6bn. AI semiconductor revenue reached $16.7bn, up 221%, while infrastructure software grew 29% to $8.8bn. That means AI now accounts for more than half of total revenue .

• Profitability is keeping pace. Operating income increased 171% to $16.0bn, while free cash flow nearly doubled.

So in 2026 we expect sales to be up 66% and FCF and net income to double compared to 2025 numbers backed by Q3 reports and Management guidance.

The growth is real. The duration is uncertain.

The AI outlook is even more aggressive. Management now expects approximately $115bn of AI chip revenue in FY2027 and $230bn in FY2028. The opportunity is substantial. Hyperscalers are building custom accelerators to reduce dependence on general-purpose GPUs and optimize their own AI workloads. Broadcom benefits from both the chips and the networking infrastructure connecting them.

The risk is concentration. A small number of customers account for a large share of AI demand, and their spending depends on the economics of AI infrastructure. Product transitions, competing chip designs and changes in customer spending (capex) can materially affect future growth.

The software business adds recurring revenue and stability, but it cannot make the semiconductor cycle disappear. If you look at the financial metrics table again you can observe substantial swings in the almost all metrics.

Before we buy or sell we must consider that uncertainty.

The pattern at work

Equity analysts often call that Durability Overpricing - a financial pattern where cyclicality is underestimated and a profitable stock trades at a price that assumes endless growth.

What growth does the valuation require?

The historical valuation ratios make Broadcom look extremely expensive: approximately 74x earnings and a 1.6% FCF (Free cash flow) yield. But those figures do not reflect the full 2026 earnings transformation.

We should give the company credit for its strong 2026 year. Adjusting the historical multiples accordingly leaves us with a forward P/E of 37.9x and FCF yield of 3.5%.

Valuation looks reasonable now given that industry average of ~25-35x PE and 3-5% FCF yield.

Now assume an investor wants a 15% annual return over the next five years. Also assume Broadcom matures and trades at 35x earnings or a 4% FCF yield in 2031 (still premium valuation assumptions).

Even after that and the strong 2026 year, investors still need another five years of roughly 17–18% annual profit and cash-flow growth to earn 15% annually.

Is that achievable? Consider the following:

• Management’s AI outlook provides a credible path to substantial growth through 2028.

• The business requires strong growth to continue through 2031, when the business is much larger and the current AI investment cycle may be more mature.

• History has shown that limited visibility and volatility have shaped financials

• Customer concentration and dependencies on their capital spending decisions has a huge impact.

• The bear case does not require AI demand to collapse. Growth could simply normalize earlier than expected. A business growing earnings at 10% rather than 17% can still be excellent, but it would struggle to support a 15% stock return.

Based on current metrics Broadcom stock trades above its fair value but the strong 2026 guidance and early (unaudited) results support the valuation.

The insight & verdict

Broadcom’s latest results justify a much higher earnings base than the historical X-Ray suggests. Ignoring that would underestimate the business.

But giving full credit for 2026 does not eliminate the valuation risk. It moves the question forward: can Broadcom compound an already much larger earnings base at close to 20% for another five years?

I would not call the stock a SELL simply because that hurdle is high. The AI opportunity may be large enough to support it. But I would also not call it a BUY without a greater margin of safety. HOLD is the appropriate verdict here.

How to understand stocks in seconds:

As an equity analyst I built The Financial X-Ray for my subscribers - a platform covering 800+ stocks. It serves as your digital private analyst to evaluates strengths, weaknesses and prices in seconds. Stocks with a strong X-ray quality score have performed exceptionally well since inception. Goal is to find quality at a reasonable price.

X-Ray platform

Any questions you may have, feel free to reach out.

Thanks for reading.

So the question of this article is simple:

Has SAP’s share price run ahead of the business or are the fundamentals strong enough to justify further upside?

What stands out in the numbers?

Three things make SAP’s financial profile particularly attractive.

• Profitability. EBITDA margin has moved from roughly 23% in 2021 to around 32% today, placing SAP toward the upper end of the broader software industry.

• Capital efficiency. The X-Ray shows ROIC rising from 8.2% in 2019 to 14.7% in 2025. That’s important: SAP isn’t simply investing more to grow; the returns generated on that invested capital have improved substantially beyond the cost of capital. In easy terms: that is value creation at an efficient level.

• Cash generation. SAP expects free cash flow to grow by 21% in 2026. Combined with effectively no net debt at the end of 2025, that gives SAP considerable flexibility to invest in AI and cloud, make acquisitions, buy back shares and return capital without stretching the balance sheet.

High margins, improving returns on capital, growing free cash flow and little financial leverage.

The cloud transition is working

SAP is no longer primarily the traditional licence-and-maintenance software company many investors still associate with the name.

In Q2, cloud revenue reached €6.3 billion, up 22%, while Cloud ERP Suite revenue grew even faster at 25%. Cloud now represents roughly 64% of SAP’s quarterly revenue, compared with a shrinking contribution from traditional software licences and support.

That’s important because SAP is deliberately moving customers from licences and on-premise software toward recurring cloud subscriptions.

Traditional software support revenue fell 8% in Q2, while licence revenue fell 32%. This isn’t necessarily a sign of deterioration, it is increasingly the consequence of customers moving onto SAP’s cloud products.

The current cloud backlog (the contracted cloud revenue that has not yet been recognised) reached €22.9 billion ($26.3 billion), up 27%.

That gives SAP something investors should value highly: visibility. A meaningful part of future cloud growth isn’t merely management ambition; customers have already signed contracts for it.

And there is still runway. Management expects cloud revenue to reach €25.8–26.2 billion in 2026, up 23–25%, while total revenue should grow at roughly the same 10.6% rate as 2025 before accelerating again in 2027.

The next step is turning that growth into profitability.

SAP expects operating expenses in 2027 to grow at only 80–90% of the rate of revenue growth, helped partly by efficiency gains from using its own AI products internally. In simple terms: margins are expected to expand.

That’s the first reason I’m not particularly worried about the recent rally. The growth story still has numbers behind it, and the financial benefits of the transformation may not yet be fully visible.

Behind the paywall I’ll reveal the following:

• Is 30.7x TTM earnings, 14.9x EV/EBITDA and a 3.4% free-cash-flow yield too much to pay? (Example calculation and visible fair value analysis)

• What happens if the legacy software segment breaks?

• And are we late to the party?

Read more

Effectively, American Express combines payment solutions, financing and consumption through its partnership network. That’s a strong moat. To determine whether or not the stock is a buy we have to look deeper.

What changed beneath the surface

At first we must clarify an important distinction. American Express cannot be compared to Visa or Mastercard as it also operates as a bank that assumes credit risk. Consequently we have to take a hybrid approach that evaluates banking and industrial metrics simultaneously.

• Growth: American Express has grown considerably faster than a mature financial company normally would. Revenue increased from $47.1bn in 2019 to $80.5bn in 2025.

  Excluding the pandemic disruption, growth remained above 8% every year. That matters because Amex is already a huge business: sustained high-single-digit growth at this scale is evidence that the franchise is still expanding rather than merely protecting its existing customer base.

  Growth above 20% in 2022-23 shows evidence of inflation resilience where customers spent right through inflation and Amex benefiting accordingly.

• Profitability has kept pace. Net income reached $10.8bn in 2025, versus $6.8bn in 2019. That’s a consistent growth of 8% which is high for Amex hybrid business model.

• More useful for a financial company is ROE which measures how effective the company generates profits on the shareholder capital. American Express has produced roughly 32–35% ROE since 2022 - a very strong return.

• FCF reached $15.4bn in 2025, while net debt/EBITDA was only 0.6x. Those numbers look attractive, but Amex is a bank holding company. Deposits, lending and debt are part of how it operates. Conventional FCF, EBITDA and net-debt ratios therefore tell us less than they would for industrial or tech companies. So we we put a little less weight on these metrics.

Instead, we need to look at the credit book.

And that is where the investment case gets stronger.

The bank inside American Express looks healthy

Q2 revenue increased 10%, while billed business (the amount customers actually spent on Amex cards) increased 9%. Card balances and other loans grew 8%.

Normally, growing lending deserves scrutiny. More loans can generate more interest income today while creating credit losses tomorrow. That isn’t what the current numbers show.

The technicalities: The 30+ day delinquency rate fell from 1.3% to 1.2%. Principal write-offs remained at 2.0%. Credit-loss provisions actually declined 23%. And Amex maintained a 10.4% CET1 capital ratio, inside management’s 10–11% target range.

In simple terms: Amex is lending more without yet seeing customers struggle more to repay it.

The card franchise may be even more interesting

The quality of American Express isn’t simply that people use its cards.

It is who uses them and how much Amex can earn from them.

Average spending per proprietary card increased 6% in Q2. Average annualized fee per card increased 12%, from $117 to $131. Net card-fee revenue increased 15%.

Amex is therefore getting two forms of growth from the same franchise: customers are spending more, while the company is collecting more membership revenue per card.

But there is a cost!

Card Member services expense jumped 50% in Q2 as customers used more benefits and Amex expanded its Platinum offering. That led to total expenses growing at 12%, while revenue only grew at 10%.

Premium customers are valuable but keeping them loyal isn’t free.

The pattern in a nutshell

There is no clear structural distortion case observable.

Instead, American Express requires a hybrid analysis of corporate signals and banking signals.

• Revenue & net income growth: ~8–10% above sector but slowing

• FCF: strong vs peers but volatile

• Capital efficiency (RoE): strong

• Capital base: strong with CET1 >10% (regulatory metric)

• Valuation metrics: attractive

The corporate numbers say the business is profitable.

The banking numbers tell us whether those profits are being created by taking excessive credit risk. Right now, they aren’t.

Why investors may misread the valuation

American Express trades at roughly 21x TTM earnings, compared with almost 24x based on 2025 earnings and based on an average of 20x over the past 7 years. Its FCF yield is around 6.8%.

Those numbers look inexpensive for a company producing ~10% revenue growth and >30% ROE. But comparing Amex directly with asset-light payment networks would be a mistake.

Amex deserves a lower multiple because it takes credit risk. A recession can simultaneously reduce card spending and increase customer defaults. Mastercard and Visa don’t carry that risk to the same extent.

A dividend discount model (DDM) is the most appropriate model to value American Express. Assuming an annual net income growth of 8-9% p.a (in line with history), a CET1 ratio > 10% (regulatory requirement), a discount rate of 8% (corresponding to it’s beta slightly above 1) yields a fair value of $ 220bn while the business is currently worth $ 225bn.

So does the current price level sufficiently compensates investors for the additional credit risk?

Today, the evidence says yes but not overwhelmingly so. The Financial X-Ray supports the results from the DDM above by taking the metrics discussed herein and by adjusting the valuation multiples accordingly. The result is displayed visually.

A transparent view on what the X-Ray does can be found on my website where I cover 800+ stocks using the exact same framework to see strengths and weaknesses in seconds.

X-Ray Methodology

The insight

American Express looks like a Buy, but not a deep-value one.

The investment case rests on an unusual combination: roughly 10% revenue growth, 36% ROE, increasing card spending, rising membership fees and currently healthy credit quality.

The risk is equally clear. Expenses are growing quickly, the company carries consumer credit risk, and its premium customer economics depend on continuing to offer benefits customers actually value.

The attraction is that investors currently get some of the economics of a premium payments franchise without paying a premium payments-network valuation.

At today’s price, that looks attractive enough.

Disclaimer: This is not investment advice to buy sell or hold any security.

They become much harder to evaluate when growth slows, losses persist and shareholders are diluted through stock-based compensation. We’ve seen this across many AI and software stocks recently.

The Financial X-Ray applies a consistent framework to evaluate financial health, management quality, growth and valuation together with a simple purpose.

To buy quality stocks at decent prices.

To outperform the market without loading up on risk.

I store the results across 800+ companies on my website, ready for you to inspect.

Stocks with an X-Ray score of strong have outperformed the S&P 500 by 50% over the past 3 years.

X-Ray platform

Today, one AI and automation company caught my attention. Its stock has fallen 81% over five years, yet the framework now rates the business Strong, with High upside.

Let’s look at the business underneath it and why it has finally become investable for the Financial X-Ray.

The numbers are changing

Revenue has grown from $336 million in 2020 to $1.61 billion in 2026. That’s an annual growth rate of 30%. Growth has slowed substantially from the early years, but accelerated slightly to 12.7% last year, and to 17% in the last quarter.

More important is what happened to profitability.

EBITDA improved from a $299 million loss in 2023 to a $118 million profit in 2026, taking the EBITDA margin from -28.2% to +7.3%. The recent quarterly report confirmed that trend bringing the margin above 8%.

That’s the transition I’m interested in.

Revenue is still growing, but increasingly more of that revenue is reaching the bottom line.

Let’s look at the convincing facts:

• Free Cash Flow: the company generated $292 million in 2024, $300 million in 2025 and $327 million in 2026. Historically that number was driven by larges amounts of stock-based compensation (a scenario where the company pays its employees with stock options to avoid a direct cash expense). Such a situation should not persist for a long time as it weakens the position of existing equity holder and eventually employees must be paid in hard cash. But the direction is encouraging: stock-based compensation is down to 53 million from 75 million in the first quarter, while share buybacks have increased.

• The business also holds substantial net cash, giving it financial flexibility while the AI market develops. A large amount of debt would be paralysing at this stage as it constraints the free allocation of capital.

So this is no longer a business promising that cash generation will eventually arrive.

It’s already here.

There is one number I’d largely ignore.

Net income jumped to $282 million in 2026, producing a 17.5% net margin. A large tax benefit contributed to that result, so I wouldn’t extrapolate the headline earnings.

Fortunately, the investment case doesn’t need it.

Positive EBITDA and three consecutive years of substantial free cash flow provide much cleaner evidence of improving underlying economics.

Stock-based compensation remains the biggest financial concern.

That’s something I’ll continue watching closely.

Why the X-Ray bought it

Put everything together:

• Revenue growth is reaccelerating.

• EBITDA has turned positive.

• Free cash flow has exceeded $290 million for three consecutive years.

• The balance sheet is strong.

• Stock-based compensation is moving in the right direction.

• And valuation no longer requires extraordinary future growth.

The stock currently offers a 4.7% free-cash-flow yield, while the Financial X-Ray rates its valuation Strong.

That’s why the algorithm selected it.

What could prove us wrong?

The transition is far from complete.

ROIC is only 3.4%. Profitability has a short track record. Stock-based compensation remains high. And the competitive position is only rated Medium.

Then there’s AI itself.

AI creates enormous demand for automation, but it also lowers technological barriers and increases competition.

So the question is whether this company can remain an important part of how enterprises deploy automation as AI becomes more capable.

That’s what I’d watch.

The Financial X-Ray simply tells us here:

The financial evidence has improved enough, and the valuation has fallen far enough, for the potential return to justify the remaining risks.

The stock is now part of the portfolio with a small 2% capital allocation. I see an upside potential but it comes at a certain risk worth taking.

Behind the paywall I’ll reveal the companies name and its moat.

Paid subscribers have access to the

• Flagship articles highlighting stock ideas (like this one)

• Entire X-Ray portfolio selection (that has outperformed the S&P 500 consistently)

• Full database covering 800+ stocks (explore 100 stocks for free)

• Roast my portfolio function and let the framework evaluate your portfolio

• Full access to the algorithm and it’s logic

• “Ask me anything, anytime” - access

All available on my website:

Full Access

Read more

Revenue split: iPhone 53%, Services 25% (App Store, iCloud, Music, TC) Wearables & iMac & iPad 22%.

The problem has not been profitability. It has been growth. But In Q3 2026 growth is back at 16% - is that a buy signal?

To answer that question let’s dive into the financials.

What changed beneath the surface

A short glimpse at the block at the bottom right reveals: This is not cheap. Stable compounders are expected to trade at a FCF yield of 3-4% (not 2.2%), a PE ratio of 25-30x (not 40x) and and EV / EBITDA of 15-20x (not 27x). Values closer to Apples historical levels.

→ A short recap on what these metrics mean and how to evaluate them HERE.

Apple’s historical financials explain why investors are willing to pay a premium.

Revenue increased from $260 billion in 2019 to $416 billion in 2025 - an annual growth of 8% - that’s decent but not impressive.

The more impressive numbers sit below revenue.

• Net margin increased from 21% to 27% showing that the business is getting more cost efficient while defending market share. Only companies with a strong competitive advantage can achieve that in such a stable manner.

• ROIC increased from 19.6% to 32.1%. In plain words: Every dollar invested generates substantially more value, a sign of efficiency. For comparison: a normal ROIC for such as business is only 12%.

• Net debt fell from $109 billion in 2022 to $76 billion in 2025 strengthening the balance sheet. Banks look at the Net debt to EBITDA ratio which is at 0.5x - an extremely strong value (below 1.5x is considered strong).

• And Apple generated approximately $100 billion of FCF in 2025 with a constant trend.

Apple requires surprisingly little physical investment. Only 3% of the companies sales are reinvested in the business. Amazon, Google or Meta use rates of above 20% during the AI boom.

That means management does not yet see a reason to commit tens of billions of shareholder capital to infrastructure before the economics of AI monetization become clearer.

The Financial X-Ray consequently rates management quality Strong, highlighting disciplined capital allocation and reliable forecasting.

But restraint only creates value if Apple is right.

That means for now Apple can generate enormous profits without continuously pouring a large share of its revenue back into factories and infrastructure.

Q3 2026

In Q3 2026, revenue increased 16% to $109.4 billion. iPhone sales reaccelerated sharply by 22%, with the Services segment expanding double digits as well. That’s an increase we haven’t seen in 4 years. Profitability and cash generation are equally strong.

Greater China is particularly relevant because weakness there had been one of the major concerns surrounding Apple.

That changes the investment discussion. A return to double-digit growth makes the premium easier to defend.

The pattern at work

Apple doesn’t fit one of the negative Financial X-Ray patterns we’ve discussed.

The financial picture is remarkably clean:

• Revenue: growth reaccelerating in Q3

• Net margin: strong at ~27%

• FCF: medium due to weak growth

• ROIC: strong >30%

• Management quality: strong

• Valuation: normal

The tension is the gap between business quality and the return investors can reasonably expect from today’s price.

Valuation & why investors may misread it

Look at Apples current valuation of $4.45T today. It generates approximately $100 billion of annual FCF = a yield of 2.2% ( below the historical average of 3-4%).

Investors accept that low current cash return because they expect Apple’s cash generation to grow substantially.

Now assume Apple’s valuation gradually normalizes and the stock trades at a still-premium 3% FCF yield in five years.

For you to make a 10% annual return on the stock for five years, FCF would need to grow at 17%. If the yield stays at 2.2%, FCF would have to grow by 10%.

Now compare that with history.

From 2019 to 2025, FCF compounded at only around 9% annually.

The Financial X-Ray does the thinking for you and visualizes the fair value in a chart.

With the stock trading near the upper end of the fair value band investors should expect a lower return from an investment.

The insight

Apple’s financial quality is difficult to fault.

Margins are around 35%. ROIC exceeds 30%. Capex remains unusually low. Debt is declining. The company generates around $100 billion of FCF annually, and Q3 suggests revenue and iPhone growth may be reaccelerating.

Management’s reluctance to join the AI infrastructure spending race may ultimately prove sensible. Apple has the financial strength to invest when the economics justify it rather than simply because competitors are spending.

But investors are already paying heavily for that quality.

At a 2.2% FCF yield, a 10% annual return becomes difficult if Apple’s valuation moves even modestly toward historical norms. At a 3% FCF yield five years from now, roughly 17% annual FCF growth would be required to support that return.

It is achievable, but not a free lunch.

The Financial X-Ray makes the distinction visible: the business has exceptional margins, capital efficiency and management quality. The investment case depends on whether future cash-flow growth can justify the valuation investors already place on those strengths.

Perform that a quick sanity check on financial strength, management quality and valuation across any stock in the X-Ray universe. Stocks with an X-Ray score of strong have outperformed the S&P 500 significantly.

Explore the X-Ray

A framework is only as good as the results it produces, that’s why I like to start with the facts first:

• Stocks that were selected by the Financial X-Ray have returned 141% since inception in June 2023. The S&P 500 has returned 85% over the same period.

• The portfolio consists of 40 stocks with no position larger than 3%

This is not proof that I found a magic formula because 3 years is not 20 years. But it is evidence enough that this framework deserves attention.

The approach

The Financial X-Ray approach is as simple as it can be - find quality stocks at attractive prices without chasing hype.

Therefore, I screen 800+ stocks for financial health, management quality, growth outlook and a fair valuation.

Each category contains several metrics that are tested for stability, evaluated over time and in comparison with peers. A low PE ratio means little if profitability breaks, growth is less important if debt accumulates and a strong margin can be deceptive if the capital spending is simply too high to maintain it.

The key: we have to read financials together as a system.

The Financial X-Ray was designed to interpret and balance hundreds of raw metrics for you and to return a simple traffic light assessment per category.

Details on what metrics were analysed (margins, cash flows, capital efficiency, share based compensation etc) can be found when you click on “view report” .

So basically anyone is welcome to sanity check a stock in seconds.

The tool is accessible to you on my website.

The selection

Now what companies are truly worth owning according to the framework? Of course, everyone likes to find the next 100 bagger, but the probability of finding these consistently is close to zero. Instead we can find quality stocks with limited downside risk trading at attractive prices.

So what’s inside the portfolio? I like to flag 3 positions here.

• Vertiv is up 80% since its addition about a year ago. The company provides digital infrastructure solutions such as power management, cooling, and monitoring for data centers and communications. It’s competitive position is outstanding and characterised by strong margins, high ROE, and stable revenue growth. Free cash flow aligns with sector averages, underscoring commercial strength and the importance of ongoing capital discipline.

• Trane Technologies up 210% since its addition in June 2023. It designs, manufactures, and services HVAC and transport refrigeration systems globally. While cash generation is only average, Trane’s strong ROE, stable revenue growth, strong capital efficiency and strong balance sheet support its position as a market leader.

• The Travelers Companies is up 130% since it was added in June 2023. It is a major property and casualty insurer, serving commercial and personal clients in the U.S. and internationally. Even though Travelers displays average net margins for the sector, its strong return on equity, high premium income growth stability, and operating excellence across all three business segments make Travelers stick out.

Closing words

In all cases you see that financial statements actually reveal a lot about an economic moat, a true strength. A company without pricing power cannot show superior margins over time. One without an efficient use of its capital will hardly grow over time.

It is intentional, not to focus on the most recent quarter, the next growth leg or news.

Eventually, quality sits in the numbers, and shows up consistently over time. That’s where I believe private investors can find better returns at reasonable risk.

You can see the entire portfolio of stocks and the ones that are rated “cheap” here:

See portfolio

Paid subscribers benefit from full platform access to sanity check more than 800 stocks, build and roast their portfolio and get full transparency on portfolio movements - all based on the same framework.

Thanks for reading.

Nick

The investment case looks straightforward: free cash flow has recovered, debt is falling and the stock trades at roughly 11.5x earnings.

But airlines have structurally difficult economics. Aircraft require continuous investment, margins are relatively thin, fuel prices are largely outside management’s control and demand is cyclical.

So what changed beneath the surface

Delta’s recovery since the pandemic is real.

Revenue reached $63.4 billion in 2025, up from $47.0 billion in 2019. FCF recovered to $3.6 billion, while net debt fell from $27.3 billion in 2022 to $16.8 billion.

Those are meaningful improvements. Delta is generating cash again and repairing its balance sheet.

But the quality of those earnings matters.

EBITDA margins have generally remained around 10–15% since 2022, versus 19.3% in 2019, while ROIC was only 3.1% in 2025. ROIC measures the operating profit per dollar invested and a level above the companies cost of capital (approx 8-10%) would be value accretive.

Why does that matter?

Airlines require enormous amounts of capital to generate their revenue. Aircraft need to be purchased, maintained and eventually replaced. A low return on invested capital therefore tells us that large amounts of investment have historically produced relatively modest economic returns.

That is very different from a capital-light business that can grow without continuously reinvesting billions.

Q2 shows the problem: Delta’s latest quarter was not weak from a demand perspective. Adjusted revenue increased 13.9%. Passenger revenue grew 13%, premium revenue 17% and loyalty-related revenue 19%, while capacity increased only around 1%.

That is strong commercial performance. But operating expenses increased 20%. Fuel expense increased 77%, while even non-fuel unit costs rose 6.8%.

The result:

• Revenue: +13.9%

• Operating income: -24%

• Operating margin: 13.3% → 8.8%

• Free cash flow: $733m → $209m

This is the central issue.

Delta sold substantially more, but kept substantially less.

Fuel prices were the largest driver, and Delta cannot control them. Higher ticket prices can compensate, but only to a point because passengers can switch airlines or reduce travel altogether. As a buffer against oil-price shocks and as a competitive advantage, Delta owns the Monroe refinery that generated an operating profit 350 million in Q2, however not enough to offset the risen input costs.

That makes future profitability inherently harder to predict.

The pattern that becomes visible

The Financial X-Ray let’s you identify strengths and pain points in seconds and shows a mixed picture for Delta:

• Revenue growth: slowing

• Margins: low and volatile

• Free cash flow: improving but unpredictable

• Net debt: improving

• ROIC: weak

• Valuation: attractive

There is no obvious financial red flag. This pattern reminds me of a Balance Sheet Mirage, where a strengthening balance sheet (improving debt and robust equity) mask a weakening operating engine.

The problem here is not weakness, it’s robustness.

Delta’s financial results depend heavily on variables management cannot fully control. That reduces confidence in any valuation based on a single year’s earnings or cash flow. In a nutshell, the X-Ray assigns a neutral rating to Delta, summarized below.

Why investors may misread the valuation

Let’s revisit the financial metrics table above. At roughly 11.5x earnings, Delta looks cheap. Most industrial businesses trade at 15-25x earnings.

But low multiples should be interpreted differently depending on the business behind them.

A company with recurring revenue, 30% net margin and predictable cash flows deserves a higher multiple because investors can place greater confidence in future earnings.

Delta has 10–15% EBITDA margins, significant capital requirements, volatile fuel costs and cyclical demand.

That uncertainty deserves a discount.

The historical FCF numbers make the point:

2019: $3.6bn
2020: -$7.8bn
2021: ~$0
2022: -$0.9bn
2023: $1.0bn
2024: $2.9bn
2025: $3.6bn

2026 guidance: $3-4bn

COVID explains the extreme years, but it also demonstrates how exposed airline economics are to external shocks. Right after the Pandemic, Berkshire sold all of its Airline stocks, not because of fear but because of a lack of visibility.

So the question isn’t: “Is 11.5x earnings cheap?”

It is: “Is 11.5x or 6% FCF yield cheap enough for this level of earnings uncertainty?”

Recall that investors who ask for a 10% annual return on their stock investment must also expect an annual 10% increase in FCF or earnings given the respective multiples stay at 11.5x and 6%. In 5 years, we’d have to look at a FCF of $6.8bn up from $3.5bn in 2026 (guidance) and earnings of $7.4bn up from $4.5bn.

Assuming that we’d expect a slightly higher earnings multiple of 15x and a FCF yield of 5% (optimistic airline assumptions) in 5 years, we’d still have to see 5% growth on both metrics per year.

This hasn’t been achieved over the past 7 years and judging by the variability of margins and capital spending, I do not feel comfortable making that bet.

The Financial X-Ray captures that thinking for you. The stock is cheap, but it’s balance sheet support is not enough to rate it “strong” on the X-Ray score.

The insight

There are reasons to like Delta.

Debt is falling. FCF has recovered. Premium revenue is growing faster than the main cabin, and loyalty-related revenue increased 19% in Q2. Management still expects $3–4 billion of FCF in 2026 despite the current fuel headwind.

But Q2 also provides a useful reality check:

Revenue +14%. Operating profit -24%.

That is why Delta trades at a low multiple.

The stock may still be undervalued. But this looks less like a wonderful business temporarily offered at a bargain price and more like an average business available at an attractive price.

For investors, those are two very different propositions.

The Financial X-Ray makes that distinction visible: not simply whether a stock is cheap, but whether the quality and predictability of the underlying business justify taking advantage of that price.

Stocks rated “strong” on the Financial X-Ray Score have outperformed the S&P 500 since inception. I track that performance on my website. Hit the button below and give it a look.

Thanks for reading.

Financial X-Ray

Good businesses make money. Good businesses bought at attractive prices can make considerably more - and that’s the journey I’d like to share with you

The difficult part is deciding when those two conditions actually meet.

A company can have an exceptional balance sheet and still be too expensive. A stock can look cheap while its underlying business deteriorates. And a falling share price tells us almost nothing about whether the expected return has actually improved.

That’s why I built the Financial X-Ray as a systematic framework.

Every month, it evaluates more than 800 companies across financial health, management quality, growth, valuation and competitive strength. A company only enters the Selection when those factors collectively become strong enough to justify allocating capital.

That discipline has mattered.

I don’t show this chart because I expect that gap to widen every year.

I show it because it illustrates what the framework is trying to achieve: attractive returns without needing to predict the next market winner.

And this month, the algorithm made two new decisions.

It added two businesses to the Financial X-Ray Selection.

One has fallen 22.8% this year.

The other is down 12.9%.

They operate in completely different industries. Their growth profiles are different. Their risks are different. Even the reasons investors have become cautious are different.

Yet the Financial X-Ray reached the same conclusion:

The price now compensates us sufficiently for those risks.

That makes them particularly interesting.

Two very different paths to the same conclusion

Before revealing the companies, let’s remove their names and look at what the framework sees.

Company A offers an attractive growth profile, strong cash generation, low debt and attractive valuation backed by the balance sheet.

There is no such thing as the perfect company. Every stock has a risk profile. The Financial X-Ray is build to show you these risks and it flags important trend signals. Cash flow is volatile, debt is rising and forecast visibility is limited.

It is important to be aware of these circumstances and to evaluate them in context. The green light does just that for you.

The company’s share price is down 22.8% this year. Underneath that decline, however, the financial picture has been moving in the opposite direction.

The Financial X-Ray currently rates the business Strong overall, with Strong financial health, Strong growth and Strong valuation.

The first reason is improving profitability.

EBITDA margin fell sharply from 56% in 2021 to just 24.2% in 2022. Since then, it has recovered to 41.3% in 2025, an exceptional level of profitability.

More importantly, margins aren’t recovering while the business stagnates. Revenue growth accelerated from 5.1% to 15.6% in the latest year.

That combination matters.

When revenue growth accelerates while margins expand, earnings can grow considerably faster than sales. The company isn’t simply getting bigger; the economics of each incremental dollar of revenue are improving.

Cash generation supports that picture. Free cash flow exceeded $22 billion in 2025. It has shown some year-to-year variability, but remains substantial, while net debt of only 0.9× EBITDA leaves the balance sheet with plenty of room to manoeuvre (when net debt divided by EBITDA stays below 2x, banks usually regard a business as financially flexible).

So far, we have a growing business, margins back above 40%, strong cash generation and manageable leverage.

The stock currently trades at around 17.7× TTM earnings, while its free-cash-flow yield is approximately 4%. EV/EBITDA stands at roughly 12.1×.

For context, comparable businesses in the industry currently tend to offer free-cash-flow yields below 3% while P/E multiples frequently exceed 25×.

In simple terms, investors are currently paying a lower multiple of earnings while receiving more free cash flow for every dollar invested.

That’s why the Financial X-Ray doesn’t merely see a good business. It sees an increasingly attractive risk/reward equation.

So why is the stock down?

Because the risks are real.

Regulation remains important. Geographic and product concentration are high, and free cash flow has historically been more variable than the headline 2025 number might suggest.

You can see why the Financial X-Ray flags these issues.

But you can also see why they aren’t enough to overturn the investment case.

The balance sheet isn’t signalling financial stress. Growth isn’t deteriorating. Margins aren’t collapsing. And the valuation isn’t asking us to ignore those risks.

The risks are present, but the price increasingly compensates us for taking them.

And that brings us to the conclusion:

Strong business. Strong financial foundations. And a price that has fallen far enough for the expected return to become attractive.

The stock wasn’t selected because it fell 22.8%.

It was selected because the price fell while the underlying financial evidence remained strong and in several areas continued to improve.

That’s the distinction that makes investing interesting.

Behind the paywall you’ll see the second company and the full names.

To see what companies the FInancial X-Ray flags as attractive investments (the portfolio) and where financial health, management, growth and valuation offer an attractive risk return profile explore the platform.

X-Ray platform

Read more

Its platform lets advertisers decide where, when and at what price to buy digital advertising across connected TV, video, audio and other channels.

Unlike Google or Amazon, it does not own the advertising inventory it recommends. It primarily earns fees based on the advertising spend processed through its platform.

That model has historically produced something investors value highly: growth without requiring large amounts of capital.

Investors once paid extraordinary multiples for that combination.

Today, they don’t.

Has the price deteriorated more than the business?

In order to answer that question and to see whether the current valuation level is justified we must take a look at the financials first.

The changes I see beneath the surface

The historical financials explain why the selloff deserves attention.

• Revenue increased from roughly $661 million in 2019 to $2.9 billion in 2025. That’s an annual growth of 28% over 7 years. Few companies in the technology field achieve that.

• EBITDA which reflects the profitability of the operating business increased to a new high of 26% after it fell in 2021/22. During that time the company invested aggressively in people, sales, technology and the infrastructure required to support a much larger advertising platform.

• Net debt has stayed negative throughout the entire time indicating full financial flexibility. This is a strong quality signal for a growing tech business.

• Free cash flow rose from only $20 million to $791 million consistently. That matters because growth alone does not create value. Companies can grow by spending aggressively or by accumulating debt. The stronger signal is when additional revenue produces more cash without requiring proportionally more capital. That’s exactly what The Trade Desk did.

• Return on invested capital (ROIC) shows an improvement to 8% over the past year. That figure measures the profitability on the capital spent and is a measure of efficiency. While improving, the level is not satisfactory yet and it must increase further to ~12%.

So what’s the point behind the recent selloff? Lets look at Q2 2026.

• Revenue growth decelerated to 7% (first 6 months) and to 3% in Q2 only (vs 18% a year earlier)

• Net margins decreased to 7.4% (first 6 months) and recovered to 9% in Q2 (vs 15% a year earlier)

That’s alarming! Even as operating cash flow increased by 20% in the first half, the increase is not entirely sustainable due to simple working capital working capital changes.

So this is not currently a story of financial deterioration. The cash machine still works. It is a story of predictability and certainty about how fast the business can grow and scale.

The pattern I see

The latest quarter changed the picture.

• Revenue growth: Sharp slowdown

• Operating margins: High but weakening

• Free cash flow: Strong

• Balance sheet: Net cash (strong)

• Capital efficiency: below expectations

• Valuation: Strongly compressed (cheap)

A company growing 20% can justify a much higher valuation than the same company growing 3%. At 20%, revenue roughly doubles every four years. At 3%, it takes more than two decades.

So the market is repricing the future growth embedded in the stock.

And we do not yet know whether that repricing has gone too far.

Why investors may misread this phase and valuation

For years, investors faced: Strong business + high growth + extreme valuation.

The Trade Desk repeatedly traded above 100x earnings. At those prices, investors needed years of exceptional growth simply to justify what they had already paid.

Today, the equation looks closer to:

Strong business with shaky margins + uncertain growth + compressed valuation.

That dramatically changes the return mathematics.

Say investors expect a 10% annual stock price increase over a decade and assuming The Trade Desk maintains its resilience as a business model in a stable market, it is straight forward to assume that such a business would trade at 30x earnings a decade from now. That implies a growth of only 5% per year, slightly more than the most recent quarter. But it also implies that margins do not weaken further.

That is a far easier hurdle than when investors were paying more than 100x earnings.

But this is also where the latest results matter.

Even if the investment case now considers the recent 3–7% growth as a new structural reality instead of a temporary slowdown, the numbers are achievable. Once growth returns to 10% per year investors can expect an annual stock price increase of 15% - an extraordinary return.

The stock does not need to return to its old valuation to generate attractive returns. But the business does need to recover some of its old growth and maintain profitability.

The Financial X-Ray captures the tension of declining growth and resilient fundamentals. The fair value band sits comfortably above current levels with a margin of safety but it is slightly declining to reflect the challenges of uncertainty.

The Trade Desk’s valuation has compressed sharply as growth expectations have fallen.

The insight

The Trade Desk is no longer difficult to own because of its valuation.

It is difficult to value because of its growth.

The company still generates substantial cash, carries little financial risk and has historically converted growth into increasingly attractive economics. Meanwhile, the collapse in the share price has substantially reduced the expectations investors must pay for upfront.

That creates potential upside. But it is not a free lunch.

If growth returns toward sustainable double digits, today’s valuation could offer an attractive combination of business quality and price.

If low-single-digit growth becomes normal, much of the apparent discount may simply reflect a business entering a slower phase.

The opportunity therefore isn’t that the stock has fallen.

It is the possibility that expectations have fallen further than the underlying earning power of the business.

These conclusions can be derived from a simple Financial X-Ray framework that analyses financial health, management quality, growth and valuation together and over time across 800+ stocks. Stocks selected by the framework have consistently outperformed the S&P 500.

Financial X-Ray